Hi-Tech Pharmacal, Mission Pharmacal to market new kidney stone treatment

AMITYVILLE, N.Y. Hi-Tech Pharmacal and Mission Pharmacal Co. are planning to market a new treatment for kidney stones to doctors starting in April, the drug maker announced Wednesday.

Under a license agreement between the two companies, Hi-Tech will promote UroCit-K 15mEq (potassium citrate) extended-release tablets to primary care physicians through subsidiary ECR Pharmaceuticals, while Mission will promote it to urologists. The drug is a twice-daily treatment.

“We are pleased to introduce another unique prescription branded product to the primary care market,” Hi-Tech president and CEO David Seltzer said in a statement. “UroCit-K 15mEq is a highly effective product, available in a convenient dosing regimen which will increase patient compliance.”